HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Chang, J. T. Articles by Cheng, A.-J. Search for Related Content PubMed PubMed Citation Articles by Chang, J. T. Articles by Cheng, A.-J. Related Collections Clinical Immunology Cancer Diagnostics (since 2002) Proteomics and Protein Markers

Enzyme Immunoassay for Serum Autoantibody to Survivin and Its Findings in Head-and-Neck Cancer Patients

¹ Department of Radiation Oncology,³ Department of Otorhinolaryngology, Head and Neck Surgery, and⁴ Division of Hematology/Oncology, Department of Internal Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan;² Institute of Public Health, National Yang-Ming University, Taipei, Taiwan;⁵ School of Medical Technology, Chang Gung University, Taipei Chang Gung Head and Neck Oncology Group, Taoyuan, Taiwan

^aaddress correspondence to this author at: School of Medical Technology, Chang Gung University, 259 Wen-Hwa 1st Road, Taoyuan 333, Taiwan; fax 886-3-2118247, e-mail ajchen@mail.cgu.edu.tw

The first 20% of the full text of this article appears below.

Several proteins associated with malignant transformation of cells can induce autoantibodies (1)(2)(3)(4). These autoantibodies, such as those to p53, are detectable in serum and may serve to monitor tumor progression (4)(5). Survivin, a recently cloned 16.5-kDa apoptosis inhibitor belonging to the IAP3 family (6), is expressed in the G₂-M phase of the cell cycle (7). Its overexpression in cancer is thought to overcome an apoptotic checkpoint and favor aberrant progression of transformed cells through mitosis. Survivin is not produced in adult tissues except for the thymus and placenta, but it is abundantly produced in fetal tissues and in various human tumors, including lung, colon, gastric, breast, and bladder cancers as well as high-grade lymphomas (6)(7)(8)(9)(10). We developed an enzyme-labeled assay to measure anti-survivin autoantibody in sera and evaluated the relationship between anti-survivin and clinicopathologic variables.

We obtained blood from 294 consecutive patients, before cancer treatment, at the Otorhinolaryngology or Head and Neck Surgery Clinics at Chang Gung Memorial Hospital with written informed consent. The standard treatment was radical surgery for early-stage patients, plus adjuvant radiotherapy for intermediate-risk patients, such as those with close surgical margins or lymph node metastases. Concomitant chemoradiotherapy was given to patients with lymph node metastases and extracapsular spread. All cancers were histologically graded as well-differentiated, moderately differentiated, or poorly differentiated, according to the WHO classification (11). Tumor pathology staging was classified according to the system of the American Joint Committee on Cancer (12). Blood samples from 40 gender- and age-matched healthy individuals were obtained as controls. After centrifugation, the sera were stored at –20 °C until use.

Survivin cDNA was obtained . . . [Full Text of this Article]